News for Catalyst Biosciences, Inc. (CBIO)

News for Catalyst Biosciences, Inc.
Date Headline
Jan 04, 2018 08:00 AM Catalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors
Dec 22, 2017 12:15 PM Catalyst Biosciences Announces Closing of Public Offering of Common Stock
Dec 20, 2017 06:34 PM Catalyst Biosciences Inc (NASDAQ:CBIO): Is Healthcare Attractive Relative To NasdaqCM Peers?
Dec 20, 2017 09:11 AM Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
Dec 19, 2017 04:51 PM Catalyst Biosciences Announces Proposed Public Offering of Common Stock
Dec 18, 2017 08:00 AM Catalyst Biosciences Announces Acceleration of Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B
Dec 15, 2017 08:10 AM Today’s Research Reports on Trending Tickers: Catalyst Biosciences and Valeant Pharmaceuticals
Dec 14, 2017 08:30 AM Catalyst Biosciences Announces Appointment of Edward Williams to its Board of Directors
Dec 11, 2017 08:00 AM Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference
Nov 29, 2017 03:07 PM Was Catalyst Biosciences Inc’s (CBIO) EPS Decline A Part Of Broader Industry Downturn?